Unveiling the novel immune and molecular signatures of ovarian cancer: insights and innovations from single-cell sequencing

Front Immunol. 2023 Nov 1:14:1288027. doi: 10.3389/fimmu.2023.1288027. eCollection 2023.

Abstract

Ovarian cancer is a highly heterogeneous and lethal malignancy with limited treatment options. Over the past decade, single-cell sequencing has emerged as an advanced biological technology capable of decoding the landscape of ovarian cancer at the single-cell resolution. It operates at the level of genes, transcriptomes, proteins, epigenomes, and metabolisms, providing detailed information that is distinct from bulk sequencing methods, which only offer average data for specific lesions. Single-cell sequencing technology provides detailed insights into the immune and molecular mechanisms underlying tumor occurrence, development, drug resistance, and immune escape. These insights can guide the development of innovative diagnostic markers, therapeutic strategies, and prognostic indicators. Overall, this review provides a comprehensive summary of the diverse applications of single-cell sequencing in ovarian cancer. It encompasses the identification and characterization of novel cell subpopulations, the elucidation of tumor heterogeneity, the investigation of the tumor microenvironment, the analysis of mechanisms underlying metastasis, and the integration of innovative approaches such as organoid models and multi-omics analysis.

Keywords: multi-omics; ovarian cancer; single-cell sequencing; spatial transcriptomics; transcriptomics; tumor heterogeneity; tumor immunology; tumor microenvironment.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Epigenome
  • Female
  • Humans
  • Multiomics
  • Organoids
  • Ovarian Neoplasms* / genetics
  • Technology
  • Tumor Microenvironment / genetics

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the Clinical Research on Precise Diagnosis and Treatment of Gynecologic Malignancies project of Hebei Province, China (Grant No. 21377706D); the Innovative Capacity Improvement Plan of Hebei Province (Grant No. 20577705D); the Cooperative Basic Research Program of Beijing-Tianjin-Hebei (Grant No. H2020206647); the Natural Science Foundation of Hebei Province (Grant No. H2023206356); the Excellent Clinical Medicine Talent Training Project funded by the Hebei Provincial Government in 2024 (Grant No. ZF2024040).